8% to EPS); FY17 results end Feb; FDA comments through 2018 Related DB Research: What's going on (Gallagher) You can't have your cake and eat it (Gallauherl We see potential for 50% TSR over the next two years Operational drivers: 27.8% EV/EBITDA remains at 12.3x 1.3% 0% 10% 20% • EBITDA (operatio